# Source index

Maps machine-readable content back to the official PDF.

| Content | Machine ID | PDF pages |
|---|---|---:|
| Annual Report 2026 | `sec-annual-report-2026` | 1 |
| Tetratherix Limited ACN 607 771 077 ASX:TTX Tetratherix Limited 2026 | `sec-tetratherix-limited-acn-607-771-077` | 1 |
| About this Annual Report | `sec-about-this-annual-report` | 2 |
| An Introduction to Tetratherix | `sec-an-introduction-to-tetratherix` | 3 |
| Our Tetramatrix PlatformTechnology | `sec-our-tetramatrix-platformtechnology` | 3 |
| Table of Contents | `sec-table-of-contents` | 4 |
| 01. 2026 in Review | `sec-01-2026-in-review` | 5 |
| Letter From Our Chair | `sec-letter-from-our-chair` | 6 |
| Emma Cleary Non-Executive Chair | `sec-emma-cleary-non-executive-chair` | 6 |
| TTX Timeline — 15 Years in the Making | `sec-ttx-timeline-15-years-in-the` | 7 |
| 2026 Highlights | `sec-2026-highlights` | 8–18 |
| 01. 58% Growth in Patient Impact | `sec-01-58-growth-in-patient-impact` | 9–11 |
| 02. First Revenues of $4.2m* | `sec-02-first-revenues-of-4-2m` | 12 |
| 03. Completed First FDA Submission | `sec-03-completed-first-fda-submission` | 13–15 |
| 04. Production Readiness Underway | `sec-04-production-readiness-underway` | 16 |
| 05. Precision Medicine Launch | `sec-05-precision-medicine-launch` | 17 |
| 06. Paving the Path with our Pipeline | `sec-06-paving-the-path-with-our` | 18 |
| CEO FY26 Letter | `sec-ceo-fy26-letter` | 19–21 |
| 02. Our Company | `sec-02-our-company` | 22 |
| The Tetratherix Mission | `sec-the-tetratherix-mission` | 23 |
| Tetratherix by the data | `sec-tetratherix-by-the-data` | 24 |
| Active Product Programs | `sec-active-product-programs` | 24 |
| TTX by the data | `sec-ttx-by-the-data` | 25–26 |
| Global R&D Infrastructure | `sec-global-r-d-infrastructure` | 25 |
| People and Culture | `sec-people-and-culture` | 26 |
| The Tetramatrix™ Platform Technology | `sec-the-tetramatrix-platform-technology` | 27 |
| Why Does the World Need Tetratherix? | `sec-why-does-the-world-need-tetratherix` | 28 |
| 01. Rising Patient Expectations | `sec-01-rising-patient-expectations` | 28 |
| 02. Need for Cost-Effective and Decentralised Care | `sec-02-need-for-cost-effective-and` | 28 |
| 03. Easier Healthcare Delivered Wherever Care Happens | `sec-03-easier-healthcare-delivered-wherever-care` | 28 |
| How does Tetramatrix™ solve the problem? | `sec-how-does-tetramatrix-solve-the-problem` | 29 |
| Tetramatrix™ Platform Technology | `sec-tetramatrix-platform-technology` | 29 |
| 01. Universal Minimally invasive delivery | `sec-01-universal-minimally-invasive-delivery` | 29 |
| 02. Seamlessly integrates into existing workflow | `sec-02-seamlessly-integrates-into-existing-workflow` | 29 |
| 03. Biostealth: Engineered to be ignored | `sec-03-biostealth-engineered-to-be-ignored` | 29 |
| 04. Manufactured at low cost and scaled | `sec-04-manufactured-at-low-cost-and` | 29 |
| Tetramatrix™ Platform Technology - How does it work? | `sec-tetramatrix-platform-technology-how-does-it` | 30 |
| 01. Intelligent | `sec-01-intelligent` | 30 |
| 02. Modular | `sec-02-modular` | 30 |
| 03. Biomimetic | `sec-03-biomimetic` | 30 |
| Tetramatrix™ Clinical Franchises | `sec-tetramatrix-clinical-franchises` | 31 |
| Tetramatrix™ Product Portfolio - Generation 1 | `sec-tetramatrix-product-portfolio-generation-1` | 32 |
| The Tetramatrix™ Platform Technology | `sec-the-tetramatrix-platform-technology-2` | 33 |
| Bone Regeneration - Dental (Tegenix) | `sec-bone-regeneration-dental-tegenix` | 34 |
| Bone Regeneration - Ortho (TegenEOS) | `sec-bone-regeneration-ortho-tegeneos` | 35 |
| Tissue Spacing - Oncology (Tutelix) | `sec-tissue-spacing-oncology-tutelix` | 36 |
| Tissue Spacing - Ophthalmic (Optimatrix*) | `sec-tissue-spacing-ophthalmic-optimatrix` | 37 |
| Tissue Healing - Scar Reduction (TetraDerm) | `sec-tissue-healing-scar-reduction-tetraderm` | 38 |
| Precision Medicine - Drug Delivery (STEPP) | `sec-precision-medicine-drug-delivery-stepp` | 39 |
| Product Segmentation - Generation 1 | `sec-product-segmentation-generation-1` | 40 |
| A Platform Anchored by Science | `sec-a-platform-anchored-by-science` | 41 |
| The TTX Flywheel in Motion | `sec-the-ttx-flywheel-in-motion` | 42 |
| 03. Directors' Report | `sec-03-directors-report` | 43 |
| Strategic Framework and Operational Overview | `sec-strategic-framework-and-operational-overview` | 44 |
| Our Strategic Framework | `sec-our-strategic-framework` | 45 |
| FY26 Strategic Delivery | `sec-fy26-strategic-delivery` | 46 |
| Our FY27 Strategic Framework | `sec-our-fy27-strategic-framework` | 47 |
| Financial Overview | `sec-financial-overview` | 48 |
| (1) Profit and Loss | `sec-1-profit-and-loss` | 49 |
| The group has recorded a statutory loss of $9.3 million | `sec-the-group-has-recorded-a-statutory` | 49 |
| (2) Revenue and other income | `sec-2-revenue-and-other-income` | 50 |
| (3) Employee benefits expense | `sec-3-employee-benefits-expense` | 50 |
| (4) Depreciation and amortisation expense | `sec-4-depreciation-and-amortisation-expense` | 51 |
| +$0.8 million vs FY25, driven by lease for the new advanced manufacturing campus | `sec-0-8-million-vs-fy25-driven` | 51 |
| (5) Product and development expense | `sec-5-product-and-development-expense` | 51 |
| Direct product and development expense at $2.5 million +74% vs. FY25 | `sec-direct-product-and-development-expense-at` | 51 |
| (6) Administration expense | `sec-6-administration-expense` | 52 |
| Post 30 June 2025 IPO, FY26 reflects a full year of administration costs | `sec-post-30-june-2025-ipo-fy26` | 52 |
| (7) Finance costs | `sec-7-finance-costs` | 52 |
| Regeneration franchise. (8) FY25 non-recurring items | `sec-regeneration-franchise-8-fy25-non-recurring` | 52 |
| Cashflow | `sec-cashflow` | 53 |
| Total Research and Development (R&D) Investment | `sec-total-research-and-development-r-d` | 54 |
| R&D investment $5.1 million, 31% of total cash outflows, in line with IPO Use of Funds | `sec-r-d-investment-5-1-million` | 54 |
| Statement of Financial Position | `sec-statement-of-financial-position` | 55 |
| Strong cash on hand ensures robust working capital position of $29.6 million | `sec-strong-cash-on-hand-ensures-robust` | 55 |
| Governance and Risk | `sec-governance-and-risk` | 56 |
| Risks | `sec-risks` | 57 |
| Governance | `sec-governance` | 61 |
| Charters and policies | `sec-charters-and-policies` | 62 |
| Risk management framework | `sec-risk-management-framework` | 62 |
| Board Skill Matrix Score | `sec-board-skill-matrix-score` | 62 |
| Corporate Governance Structure | `sec-corporate-governance-structure` | 63 |
| Directors Information | `sec-directors-information` | 64 |
| Directors | `sec-directors` | 64 |
| Matters subsequent to the end of the financial year | `sec-matters-subsequent-to-the-end-of` | 65 |
| Meetings of Directors | `sec-meetings-of-directors` | 66 |
| Directors Profiles | `sec-directors-profiles` | 67–68 |
| Emma Cleary Non-Executive Chair | `sec-emma-cleary-non-executive-chair-2` | 67 |
| William Knox Executive Director and CEO | `sec-william-knox-executive-director-and-ceo` | 67 |
| Dr Ali Fathi Executive Director, Founder and CTO | `sec-dr-ali-fathi-executive-director-founder` | 67–68 |
| Peter Gray Non-Executive Director | `sec-peter-gray-non-executive-director` | 68 |
| Gillian Shea Non-Executive Director | `sec-gillian-shea-non-executive-director` | 68 |
| John Kelly Non-Executive Director | `sec-john-kelly-non-executive-director` | 68 |
| Directors and Company Secretary Profiles | `sec-directors-and-company-secretary-profiles` | 69 |
| Maurizio Vecchione Non-Executive Director | `sec-maurizio-vecchione-non-executive-director` | 69 |
| Atlanta Daniel Non-Executive Director | `sec-atlanta-daniel-non-executive-director` | 69 |
| Jacob Pfeffer Company Secretary | `sec-jacob-pfeffer-company-secretary` | 69 |
| Retired Directors Profiles | `sec-retired-directors-profiles` | 70 |
| David Bottomley Non-Executive Director | `sec-david-bottomley-non-executive-director` | 70 |
| Group Executive Team | `sec-group-executive-team` | 71 |
| William Knox Executive Director and CEO | `sec-william-knox-executive-director-and-ceo-2` | 71 |
| Dr Ali Fathi Executive Director, Founder and CTO | `sec-dr-ali-fathi-executive-director-founder-2` | 71 |
| Cherie Beach Chief Financial Officer (CFO) | `sec-cherie-beach-chief-financial-officer-cfo` | 71 |
| Terence Abrams Founder and COO | `sec-terence-abrams-founder-and-coo` | 71 |
| Remuneration Report (Audited) | `sec-remuneration-report-audited` | 72 |
| Remuneration Governance | `sec-remuneration-governance` | 72 |
| Non-Executive Directors’ Remuneration | `sec-non-executive-directors-remuneration` | 73 |
| Executive Remuneration | `sec-executive-remuneration` | 73 |
| (a) Approach to Setting and Reviewing Remuneration | `sec-a-approach-to-setting-and-reviewing` | 73 |
| (b) Remuneration Principles and Strategy | `sec-b-remuneration-principles-and-strategy` | 74 |
| Remuneration strategy linked to group objectives | `sec-remuneration-strategy-linked-to-group-objectives` | 74 |
| Remuneration Review Process | `sec-remuneration-review-process` | 75 |
| Details of Remuneration | `sec-details-of-remuneration` | 75 |
| Relationship Between Remuneration and Performance | `sec-relationship-between-remuneration-and-performance` | 75 |
| Non Executive Directors Executive Directors Other KMP | `sec-non-executive-directors-executive-directors-other` | 76–77 |
| Service Agreements | `sec-service-agreements` | 78–79 |
| Share-Based Compensation | `sec-share-based-compensation` | 80 |
| Additional Disclosures Relating to Key Management Personnel | `sec-additional-disclosures-relating-to-key-management` | 81–82 |
| Shares under performance rights | `sec-shares-under-performance-rights` | 83 |
| Shares issued on the vesting of performance rights | `sec-shares-issued-on-the-vesting-of` | 84 |
| Vesting date Exercise price Number of shares issued | `sec-vesting-date-exercise-price-number-of` | 84 |
| Indemnity and Insurance of officers | `sec-indemnity-and-insurance-of-officers` | 85 |
| Non-audit services | `sec-non-audit-services` | 85 |
| Proceedings on behalf of the Company | `sec-proceedings-on-behalf-of-the-company` | 85 |
| Auditors independence declaration | `sec-auditors-independence-declaration` | 85 |
| 04. Auditor’s Independence Declaration | `sec-04-auditor-s-independence-declaration` | 86 |
| 0.5 Financial Report | `sec-0-5-financial-report` | 88 |
| Financial Report Table of Contents | `sec-financial-report-table-of-contents` | 89 |
| Financial Statements 90 | `sec-financial-statements-90` | 89 |
| Notes to the Financial Statements 94 | `sec-notes-to-the-financial-statements-94` | 89 |
| Consolidated Entity Disclosure Statement 140 | `sec-consolidated-entity-disclosure-statement-140` | 89 |
| Directors’ Declaration 141 | `sec-directors-declaration-141` | 89 |
| Independent Auditor’s Report to the Members of Tetratherix Limited 142 | `sec-independent-auditor-s-report-to-the` | 89 |
| Note 1. General Information | `sec-note-1-general-information` | 94 |
| Note 2. Material Accounting Policy Information | `sec-note-2-material-accounting-policy-information` | 94–98 |
| Inventories | `sec-inventories` | 98 |
| Prepayments | `sec-prepayments` | 98 |
| Note 2. Material Accounting Policy Information (continued) | `sec-note-2-material-accounting-policy-information-2` | 99–104 |
| Earnings Per Share | `sec-earnings-per-share` | 104 |
| Comparative Figures | `sec-comparative-figures` | 104 |
| Note 3. Critical Accounting Judgements, Estimates and Assumptions | `sec-note-3-critical-accounting-judgements-estimates` | 105–107 |
| Note 4. Operating Segments | `sec-note-4-operating-segments` | 108 |
| Note 5. Revenue and Other Income | `sec-note-5-revenue-and-other-income` | 108 |
| Note 6. Net Fair Value Loss on Financial Liabilities | `sec-note-6-net-fair-value-loss` | 108 |
| Note 7. Expenses | `sec-note-7-expenses` | 109 |
| Note 8. Income Tax | `sec-note-8-income-tax` | 110–111 |
| Note 9. Cash and Cash Equivalents | `sec-note-9-cash-and-cash-equivalents` | 112 |
| Note 10. Other Receivables | `sec-note-10-other-receivables` | 112 |
| Note 11. Inventories | `sec-note-11-inventories` | 113 |
| Note 12. Prepayments | `sec-note-12-prepayments` | 113 |
| Note 13. Property, Plant and Equipment | `sec-note-13-property-plant-and-equipment` | 114 |
| Note 14. Right-of-Use Assets | `sec-note-14-right-of-use-assets` | 115 |
| Note 15. Other Financial Assets | `sec-note-15-other-financial-assets` | 116 |
| Note 16. Intangibles | `sec-note-16-intangibles` | 116–117 |
| Note 17. Trade and Other Payables | `sec-note-17-trade-and-other-payables` | 117 |
| Note 18. Share Application Monies | `sec-note-18-share-application-monies` | 117 |
| Note 19. Contract Liabilities | `sec-note-19-contract-liabilities` | 118 |
| Note 20. Deferred Income | `sec-note-20-deferred-income` | 119 |
| Note 21. Borrowings | `sec-note-21-borrowings` | 120 |
| Note 22. Lease Liabilities | `sec-note-22-lease-liabilities` | 120 |
| Note 23. Employee Benefits | `sec-note-23-employee-benefits` | 121 |
| Note 24. Provisions | `sec-note-24-provisions` | 121 |
| Note 25. Issued Capital | `sec-note-25-issued-capital` | 122–124 |
| Note 26. Reserves | `sec-note-26-reserves` | 124–125 |
| Note 27. Dividends | `sec-note-27-dividends` | 125 |
| Note 28. Financial Instruments | `sec-note-28-financial-instruments` | 126–128 |
| Note 29. Fair Value Measurement | `sec-note-29-fair-value-measurement` | 128 |
| Note 30. Key Management Personnel Disclosures | `sec-note-30-key-management-personnel-disclosures` | 128 |
| Note 31. Remuneration of Auditors | `sec-note-31-remuneration-of-auditors` | 129 |
| Note 32. Contingent Liabilities | `sec-note-32-contingent-liabilities` | 129 |
| Note 33. Commitments | `sec-note-33-commitments` | 129–130 |
| Note 34. Related Party Transactions | `sec-note-34-related-party-transactions` | 131–132 |
| Note 35. Parent Entity Information | `sec-note-35-parent-entity-information` | 132–133 |
| Note 36. Interests in Subsidiaries | `sec-note-36-interests-in-subsidiaries` | 133 |
| Note 37. Interests in Joint Ventures | `sec-note-37-interests-in-joint-ventures` | 133–134 |
| Note 38. Cash Flow Information | `sec-note-38-cash-flow-information` | 135–136 |
| Note 39. Share-Based Payments | `sec-note-39-share-based-payments` | 136–138 |
| Note 40. Earnings Per Share | `sec-note-40-earnings-per-share` | 138 |
| Note 41. Events After The Reporting Period | `sec-note-41-events-after-the-reporting` | 139–140 |
| Tetratherix Limited Directors’ Declaration 30 June 2026 | `sec-tetratherix-limited-directors-declaration-30-june` | 141 |
| Tetratherix Limited Independent Auditor’s Report 30 June 2026 | `sec-tetratherix-limited-independent-auditor-s-report` | 142–146 |
| 6.Additional Information | `sec-6-additional-information` | 147–149 |
| Tetratherix Substantial Holders | `sec-tetratherix-substantial-holders` | 149–151 |
| Corporate Directory | `sec-corporate-directory` | 152 |
| Consolidated Statement of Profit or Loss | `tbl-consolidated-statement-of-profit-or-loss` | 90 |
| Consolidated Statement of Financial Position | `tbl-consolidated-statement-of-financial-position` | 91 |
| Consolidated Statement of Changes in Equity | `tbl-consolidated-statement-of-changes-in-equity` | 92 |
| Consolidated Statement of Cash Flows | `tbl-consolidated-statement-of-cash-flows` | 93 |
| FY26 Administration Expenses ($2.3m) | `tbl-curated-p52-fy26-administration-expenses-2-3m` | 52 |
| R&D Investment by Program ($m) | `tbl-curated-p54-r-d-investment-by-program-m` | 54 |
| Working Capital ($m) | `tbl-curated-p55-working-capital-m` | 55 |
| Summary Statement of Profit and Loss ($AUD '000) | `tbl-curated-p49-summary-statement-of-profit-and-loss-aud-000` | 49 |
| Our Strategic Framework | `tbl-curated-p45-our-strategic-framework` | 45 |
| FY26 Strategic Delivery — People, Manufacturing & Governance | `tbl-curated-p46-fy26-strategic-delivery-people-manufacturing-gov` | 46 |
| FY26 Strategic Delivery — Clinically Innovative Solutions | `tbl-curated-p46-fy26-strategic-delivery-clinically-innovative-so` | 46 |
| FY27 Strategic Delivery — People, Manufacturing & Governance | `tbl-curated-p47-fy27-strategic-delivery-people-manufacturing-gov` | 47 |
| FY27 Strategic Delivery — Clinically Innovative Solutions | `tbl-curated-p47-fy27-strategic-delivery-clinically-innovative-so` | 47 |
| Active Product Programs — Stage of Development | `tbl-curated-p24-active-product-programs-stage-of-development` | 24 |
| People & Culture | `tbl-curated-p26-people-culture` | 26 |
| Tetramatrix™ Product Portfolio — Generation 1 | `tbl-curated-p32-tetramatrix-product-portfolio-generation-1` | 32 |
| Tetramatrix™ Polymer Building Blocks | `tbl-curated-p33-tetramatrix-polymer-building-blocks` | 33 |
| Product → Polymer Configuration | `tbl-curated-p33-product-polymer-configuration` | 33 |
| Product Segmentation — Generation 1 | `tbl-curated-p40-product-segmentation-generation-1` | 40 |
| A Platform Anchored by Science — Franchise Results & Platform Impact | `tbl-curated-p41-a-platform-anchored-by-science-franchise-results` | 41 |
| TTX Timeline — 15 Years in the Making | `tbl-curated-p7-ttx-timeline-15-years-in-the-making` | 7 |
| FDA Submission Readout — Mean Total Bone Volume | `tbl-curated-p14-fda-submission-readout-mean-total-bone-volume` | 14 |
| FDA Submission Readout — Standard Deviation | `tbl-curated-p14-fda-submission-readout-standard-deviation` | 14 |
| FDA Submission Readout — Bone Maturation Stage | `tbl-curated-p14-fda-submission-readout-bone-maturation-stage` | 14 |
| Tetramatrix™ Clinical Franchises | `tbl-curated-p31-tetramatrix-clinical-franchises` | 31 |
| Key Risks and Mitigations | `tbl-curated-p57-key-risks-and-mitigations` | 57–60 |
| Board Skills Matrix | `tbl-curated-p62-board-skills-matrix` | 62 |
| Meetings of Directors — Attendance | `tbl-curated-p66-meetings-of-directors-attendance` | 66 |
| Directors' Interests in the Securities of Tetratherix | `tbl-curated-p66-directors-interests-in-the-securities-of-tetrath` | 66 |
| Executive Remuneration Framework | `tbl-curated-p74-executive-remuneration-framework` | 74 |
| Remuneration of Key Management Personnel | `tbl-curated-p76-remuneration-of-key-management-personnel` | 76 |
| Remuneration Mix (% of total) | `tbl-curated-p77-remuneration-mix-of-total` | 77 |
| Cash Bonus Outcomes (% of maximum) | `tbl-curated-p77-cash-bonus-outcomes-of-maximum` | 77 |
| Performance Rights Granted | `tbl-curated-p80-performance-rights-granted` | 80 |
| KMP Shareholdings | `tbl-curated-p81-kmp-shareholdings` | 81 |
| Performance Rights Movement | `tbl-curated-p82-performance-rights-movement` | 82 |
| Performance Rights by Grant | `tbl-curated-p83-performance-rights-by-grant` | 83 |
| Shares Issued on Vesting of Performance Rights | `tbl-curated-p84-shares-issued-on-vesting-of-performance-rights` | 84 |
| Note 5. Revenue and Other Income | `tbl-curated-p108-note-5-revenue-and-other-income` | 108 |
| Note 6. Net Fair Value Loss on Financial Liabilities | `tbl-curated-p108-note-6-net-fair-value-loss-on-financial-liabilit` | 108 |
| Note 7. Expenses | `tbl-curated-p109-note-7-expenses` | 109 |
| Note 8. Income Tax | `tbl-curated-p110-note-8-income-tax` | 110 |
| Note 8. Income Tax | `tbl-curated-p111-note-8-income-tax` | 111 |
| Note 9. Cash and Cash Equivalents | `tbl-curated-p112-note-9-cash-and-cash-equivalents` | 112 |
| Note 10. Other Receivables | `tbl-curated-p112-note-10-other-receivables` | 112 |
| Note 11. Inventories | `tbl-curated-p113-note-11-inventories` | 113 |
| Note 12. Prepayments | `tbl-curated-p113-note-12-prepayments` | 113 |
| Note 13. Property, Plant and Equipment | `tbl-curated-p114-note-13-property-plant-and-equipment` | 114 |
| Note 13. Property, Plant and Equipment — Movement Reconciliation | `tbl-curated-p114-note-13-property-plant-and-equipment-movement-re` | 114 |
| Note 14. Right-of-Use Assets | `tbl-curated-p115-note-14-right-of-use-assets` | 115 |
| Note 14. Right-of-Use Assets — Premises | `tbl-curated-p115-note-14-right-of-use-assets-premises` | 115 |
| Note 14. Right-of-Use Assets — Movement Reconciliation | `tbl-curated-p115-note-14-right-of-use-assets-movement-reconciliat` | 115 |
| Note 15. Other Financial Assets | `tbl-curated-p116-note-15-other-financial-assets` | 116 |
| Note 16. Intangibles | `tbl-curated-p116-note-16-intangibles` | 116 |
| Note 16. Intangibles — Movement Reconciliation | `tbl-curated-p116-note-16-intangibles-movement-reconciliation` | 116 |
| Note 17. Trade and Other Payables | `tbl-curated-p117-note-17-trade-and-other-payables` | 117 |
| Note 18. Share Application Monies | `tbl-curated-p117-note-18-share-application-monies` | 117 |
| Note 19. Contract Liabilities | `tbl-curated-p118-note-19-contract-liabilities` | 118 |
| Note 19. Contract Liabilities — Movement Reconciliation | `tbl-curated-p118-note-19-contract-liabilities-movement-reconcilia` | 118 |
| Note 20. Deferred Income | `tbl-curated-p119-note-20-deferred-income` | 119 |
| Note 20. Deferred Income — Movement Reconciliation | `tbl-curated-p119-note-20-deferred-income-movement-reconciliation` | 119 |
| Note 21. Borrowings | `tbl-curated-p120-note-21-borrowings` | 120 |
| Note 22. Lease Liabilities | `tbl-curated-p120-note-22-lease-liabilities` | 120 |
| Note 23. Employee Benefits | `tbl-curated-p121-note-23-employee-benefits` | 121 |
| Note 24. Provisions | `tbl-curated-p121-note-24-provisions` | 121 |
| Note 25. Issued Capital | `tbl-curated-p122-note-25-issued-capital` | 122 |
| Note 25. Movements in Ordinary Share Capital | `tbl-curated-p122-note-25-movements-in-ordinary-share-capital` | 122 |
| Note 25. Restricted & Voluntary Escrow Shares | `tbl-curated-p123-note-25-restricted-voluntary-escrow-shares` | 123 |
| Note 26. Reserves | `tbl-curated-p124-note-26-reserves` | 124 |
| Note 26. Reserves | `tbl-curated-p125-note-26-reserves` | 125 |
| Note 28. Interest Rate Sensitivity | `tbl-curated-p126-note-28-interest-rate-sensitivity` | 126 |
| Note 28. Foreign Exchange Sensitivity | `tbl-curated-p126-note-28-foreign-exchange-sensitivity` | 126 |
| Note 28. Remaining Contractual Maturities — 2026 | `tbl-curated-p127-note-28-remaining-contractual-maturities-2026` | 127 |
| Note 28. Remaining Contractual Maturities — 2025 | `tbl-curated-p128-note-28-remaining-contractual-maturities-2025` | 128 |
| Note 30. Key Management Personnel Disclosures | `tbl-curated-p128-note-30-key-management-personnel-disclosures` | 128 |
| Note 31. Remuneration of Auditors | `tbl-curated-p129-note-31-remuneration-of-auditors` | 129 |
| Note 32. Contingent Liabilities | `tbl-curated-p129-note-32-contingent-liabilities` | 129 |
| Note 34. Related Party Transactions | `tbl-curated-p131-note-34-related-party-transactions` | 131 |
| Note 34. Related Party Transactions | `tbl-curated-p132-note-34-related-party-transactions` | 132 |
| Note 35. Parent Entity Information | `tbl-curated-p132-note-35-parent-entity-information` | 132 |
| Note 36. Interests in Subsidiaries | `tbl-curated-p133-note-36-interests-in-subsidiaries` | 133 |
| Note 37. Interests in Joint Ventures | `tbl-curated-p133-note-37-interests-in-joint-ventures` | 133 |
| Note 37. Interests in Joint Ventures — Carrying Amount and Share of Results | `tbl-curated-p134-note-37-interests-in-joint-ventures-carrying-amo` | 134 |
| Note 38. Cash Flow Information | `tbl-curated-p135-note-38-cash-flow-information` | 135 |
| Note 38. Cash Flow Information | `tbl-curated-p136-note-38-cash-flow-information` | 136 |
| Note 39. Share-Based Payments — Performance Rights | `tbl-curated-p137-note-39-share-based-payments-performance-rights` | 137 |
| Note 39. Share-Based Payments — Options | `tbl-curated-p138-note-39-share-based-payments-options` | 138 |
| Note 40. Earnings Per Share | `tbl-curated-p138-note-40-earnings-per-share` | 138 |
| Consolidated Entity Disclosure Statement | `tbl-curated-p140-consolidated-entity-disclosure-statement` | 140 |
| Distribution of Ordinary Share Holdings | `tbl-curated-p148-distribution-of-ordinary-share-holdings` | 148 |
| Distribution of Performance Rights | `tbl-curated-p148-distribution-of-performance-rights` | 148 |
| Twenty Largest Ordinary Shareholders | `tbl-curated-p149-twenty-largest-ordinary-shareholders` | 149 |
| Substantial Holders | `tbl-curated-p149-substantial-holders` | 149 |
| Unquoted Performance Rights — Holders of More Than 20% | `tbl-curated-p150-unquoted-performance-rights-holders-of-more-than` | 150 |
| Restricted & Escrow Shares — Holders of More Than 20% | `tbl-curated-p150-restricted-escrow-shares-holders-of-more-than-20` | 150 |
| Restricted & Voluntary-Escrow Securities | `tbl-curated-p151-restricted-voluntary-escrow-securities` | 151 |
| Corporate Directory | `tbl-curated-p152-corporate-directory` | 152 |

**155 derived financial metrics** (see `data/financial-metrics.csv`), e.g.:

| Metric | Period | Value | PDF page |
|---|---|---:|---:|
| Revenue | FY2026 | 918,151 | 90 |
| Other income | FY2026 | 2,943,577 | 90 |
| Other income | FY2025 | 1,052,616 | 90 |
| Interest Revenue | FY2026 | 795,825 | 90 |
| Interest Revenue | FY2025 | 90,030 | 90 |
| Total Revenue and Other Income | FY2026 | 4,657,553 | 90 |
| Total Revenue and Other Income | FY2025 | 1,142,646 | 90 |
| Net Fair Value Loss on Financial Liabilities | FY2025 | (3,589,550) | 90 |
| Administration Expenses | FY2026 | (2,257,967) | 90 |
| Administration Expenses | FY2025 | (1,007,333) | 90 |
| Employee Benefits Expense | FY2026 | (7,765,941) | 90 |
| Employee Benefits Expense | FY2025 | (3,108,684) | 90 |
| Depreciation and Amortisation Expense | FY2026 | (926,615) | 90 |
| Depreciation and Amortisation Expense | FY2025 | (79,923) | 90 |
| Research and Development Project Expenses | FY2026 | (2,464,170) | 90 |
| Research and Development Project Expenses | FY2025 | (1,418,723) | 90 |
| IPO Costs | FY2025 | (1,282,341) | 90 |
| Finance Costs | FY2026 | (563,395) | 90 |
| Finance Costs | FY2025 | (81,644) | 90 |
| Total Expenses | FY2026 | (13,978,088) | 90 |